Allogene Therapeutics (ALLO) Projected to Announce Quarterly Earnings on Wednesday

Allogene Therapeutics (NASDAQ:ALLO) will likely be posting its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect Allogene Therapeutics to post earnings of ($0.1714) per share and revenue of $0.0020 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 5:00 PM ET.

Allogene Therapeutics (NASDAQ:ALLO) last issued its earnings results on Wednesday, May 13th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. On average, analysts expect Allogene Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Allogene Therapeutics Stock Performance

ALLO stock opened at $1.90 on Wednesday. The stock’s 50 day simple moving average is $1.97 and its 200 day simple moving average is $2.10. Allogene Therapeutics has a fifty-two week low of $0.98 and a fifty-two week high of $4.46. The company has a market cap of $655.78 million, a P/E ratio of -2.47 and a beta of 0.48.

Institutional Trading of Allogene Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALLO. Hsbc Holdings PLC raised its stake in shares of Allogene Therapeutics by 57.5% in the fourth quarter. Hsbc Holdings PLC now owns 148,136 shares of the company’s stock worth $199,000 after purchasing an additional 54,071 shares during the last quarter. Virtu Financial LLC boosted its position in shares of Allogene Therapeutics by 55.9% during the fourth quarter. Virtu Financial LLC now owns 42,351 shares of the company’s stock valued at $58,000 after buying an additional 15,178 shares during the last quarter. Invesco Ltd. grew its holdings in Allogene Therapeutics by 16.1% during the fourth quarter. Invesco Ltd. now owns 609,807 shares of the company’s stock worth $835,000 after buying an additional 84,494 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its holdings in Allogene Therapeutics by 23.0% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 29,512 shares of the company’s stock worth $40,000 after buying an additional 5,514 shares in the last quarter. Finally, Virtus Investment Advisers LLC raised its position in Allogene Therapeutics by 116.8% in the 4th quarter. Virtus Investment Advisers LLC now owns 176,178 shares of the company’s stock valued at $241,000 after buying an additional 94,902 shares during the last quarter. 83.63% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ALLO has been the subject of a number of research reports. HC Wainwright raised their price objective on Allogene Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, April 14th. Sanford C. Bernstein upped their target price on Allogene Therapeutics from $1.60 to $3.85 and gave the stock a “market perform” rating in a research report on Tuesday, April 14th. Argus increased their target price on Allogene Therapeutics from $1.60 to $3.85 and gave the stock a “market perform” rating in a report on Tuesday, April 14th. Robert W. Baird lifted their price target on shares of Allogene Therapeutics from $7.00 to $9.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Finally, JPMorgan Chase & Co. upgraded shares of Allogene Therapeutics from an “underweight” rating to a “neutral” rating in a research note on Thursday, April 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.52.

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.